{"gene":"ZCCHC10","run_date":"2026-04-28T23:00:24","timeline":{"discoveries":[{"year":2019,"finding":"ZCCHC10 binds p53 directly and stabilizes it by disrupting the interaction between p53 and MDM2, thereby attenuating MDM2-mediated p53 ubiquitination and degradation. This interaction was functionally required for ZCCHC10's tumor-suppressive effects on cell proliferation, migration, invasion, and cisplatin resistance in lung cancer cells harboring wild-type p53, but not in p53-null or p53-mutant cells.","method":"Co-immunoprecipitation, overexpression/knockdown with functional rescue using p53 inhibitor pifithrin-α and activator Nutlin3, in vitro and in vivo tumor models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, multiple orthogonal functional assays, genetic epistasis with p53 inhibitor/activator, in vivo validation","pmids":["31138778"],"is_preprint":false},{"year":2019,"finding":"ZCCHC10 interacts with PITX1 via the PITX1 homeodomain, and the ZCCHC10-PITX1 complex cooperatively suppresses hTERT transcription. Deletion of the PITX1 homeodomain required for ZCCHC10 interaction abolished the transcriptional silencing effect.","method":"FLAG pull-down assay, co-expression studies, mutagenesis (homeodomain deletion), luciferase/transcription assays in melanoma cell lines","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — pulldown plus mutagenesis and functional transcription assay, single lab","pmids":["31404068"],"is_preprint":false},{"year":2021,"finding":"miR-410-3p directly targets the 3'UTR of ZCCHC10 mRNA, reducing ZCCHC10 protein levels. Loss of ZCCHC10 activates the NF-κB signaling pathway, promoting EMT, migration, and invasion in colorectal cancer cells. NF-κB inhibition rescued the pro-invasive phenotype caused by ZCCHC10 knockdown, placing ZCCHC10 upstream of NF-κB as a suppressor.","method":"Dual-luciferase reporter assay (miR-410-3p targeting ZCCHC10 3'UTR), siRNA knockdown, NF-κB inhibitor (BAY 11-708) rescue, wound healing and Transwell invasion assays, overexpression rescue","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase validation of direct targeting plus epistasis with NF-κB inhibitor, single lab","pmids":["33517196"],"is_preprint":false},{"year":2023,"finding":"The lncRNA SNHG1 epigenetically silences ZCCHC10 by recruiting DNA methyltransferases DNMT1 and DNMT3B to the ZCCHC10 promoter CpG island. SNHG1 contains a binding motif with complementarity to five sites in the ZCCHC10 promoter; deletion of this motif abolished SNHG1-induced ZCCHC10 promoter hypermethylation. Reduced ZCCHC10 expression leads to decreased p53 activation, increased AML cell proliferation, and venetoclax resistance.","method":"ChIP assay (SNHG1 binding to ZCCHC10 promoter, DNMT1/DNMT3B recruitment), bisulfite sequencing (promoter methylation), SNHG1 motif-deletion mutagenesis, overexpression/knockdown functional assays, xenograft mouse model","journal":"International journal of oncology","confidence":"High","confidence_rationale":"Tier 2 — ChIP, methylation assay, mutagenesis, and in vivo xenograft, moderate evidence from single lab with multiple orthogonal methods","pmids":["37052262"],"is_preprint":false}],"current_model":"ZCCHC10 is a tumor suppressor that stabilizes p53 by competitively disrupting the p53–MDM2 interaction to prevent MDM2-mediated ubiquitination and degradation of p53; it also forms a complex with PITX1 to transcriptionally repress hTERT, and acts upstream of NF-κB to suppress EMT and invasion, while its own expression is silenced by SNHG1-directed recruitment of DNMT1/DNMT3B to its promoter CpG island."},"narrative":{"teleology":[{"year":2019,"claim":"Establishing ZCCHC10 as a p53 stabilizer resolved how this previously uncharacterized zinc-finger protein suppresses tumor growth: it directly binds p53, disrupts the p53–MDM2 interaction, and blocks MDM2-mediated ubiquitination and degradation of p53, making its tumor-suppressive effects strictly dependent on wild-type p53.","evidence":"Reciprocal co-IP, epistasis with p53 inhibitor pifithrin-α and activator Nutlin-3, in vitro and xenograft lung cancer models","pmids":["31138778"],"confidence":"High","gaps":["Structural basis for the ZCCHC10–p53 interaction and the precise binding interface on MDM2 are unknown","Whether ZCCHC10 affects MDMX-mediated p53 regulation has not been tested","Endogenous stoichiometry of the ZCCHC10–p53–MDM2 competitive mechanism has not been quantified"]},{"year":2019,"claim":"Identification of ZCCHC10 as a PITX1 cofactor that cooperatively represses hTERT transcription revealed a second tumor-suppressive axis independent of p53 stabilization.","evidence":"FLAG pull-down, homeodomain-deletion mutagenesis, luciferase reporter assays in melanoma cells","pmids":["31404068"],"confidence":"Medium","gaps":["The ZCCHC10–PITX1 interaction has been shown only by pull-down in a single study without reciprocal co-IP","Whether ZCCHC10–PITX1-mediated hTERT repression is functionally relevant in vivo remains untested","The domain in ZCCHC10 required for PITX1 binding is not mapped"]},{"year":2021,"claim":"Placing ZCCHC10 upstream of NF-κB as a negative regulator explained how its loss promotes EMT, migration, and invasion in colorectal cancer, and revealed miR-410-3p as a post-transcriptional silencer of ZCCHC10.","evidence":"Dual-luciferase 3′UTR reporter assay, siRNA knockdown, NF-κB inhibitor (BAY 11-7082) rescue, wound healing and Transwell invasion assays","pmids":["33517196"],"confidence":"Medium","gaps":["The molecular mechanism by which ZCCHC10 inhibits NF-κB activation is undefined (direct vs. indirect)","Findings come from a single laboratory without in vivo validation","Relationship between ZCCHC10's NF-κB suppression and its p53 stabilization function is unexplored"]},{"year":2023,"claim":"Discovery that lncRNA SNHG1 epigenetically silences ZCCHC10 by recruiting DNMT1/DNMT3B to its promoter CpG island explained how ZCCHC10 is downregulated in cancer and linked this silencing to venetoclax resistance in AML via reduced p53 activity.","evidence":"ChIP for DNMT1/DNMT3B recruitment, bisulfite sequencing, SNHG1 motif-deletion mutagenesis, xenograft mouse model in AML cells","pmids":["37052262"],"confidence":"High","gaps":["Whether SNHG1-mediated silencing of ZCCHC10 operates across cancer types beyond AML is unknown","The extent to which ZCCHC10 promoter methylation accounts for its downregulation relative to miR-410-3p post-transcriptional silencing has not been compared","Whether restoring ZCCHC10 expression alone is sufficient to overcome venetoclax resistance in patient-derived models is untested"]},{"year":null,"claim":"How ZCCHC10's zinc-finger CCHC domain contributes to its molecular functions — including p53 binding, PITX1 interaction, and NF-κB suppression — and whether these activities are coordinated or independent in vivo remains an open question.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or domain-mapping data exist for ZCCHC10's interactions with p53 or MDM2","No unbiased interactome or proteomics study has been performed for ZCCHC10","The physiological role of ZCCHC10 in normal (non-cancer) tissues is entirely uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2]}],"complexes":[],"partners":["TP53","MDM2","PITX1"],"other_free_text":[]},"mechanistic_narrative":"ZCCHC10 functions as a tumor suppressor that stabilizes p53 by directly binding p53 and competitively disrupting the p53–MDM2 interaction, thereby attenuating MDM2-mediated ubiquitination and degradation of p53; this mechanism is required for ZCCHC10's anti-proliferative, anti-invasive, and chemosensitizing activities in wild-type p53-expressing cancer cells [PMID:31138778]. ZCCHC10 also partners with the transcription factor PITX1 via its homeodomain to cooperatively repress hTERT transcription [PMID:31404068], and suppresses NF-κB signaling to inhibit epithelial–mesenchymal transition and invasion [PMID:33517196]. ZCCHC10 expression is epigenetically silenced in cancer through lncRNA SNHG1-directed recruitment of DNMT1 and DNMT3B to its promoter CpG island, leading to promoter hypermethylation and loss of p53 stabilization [PMID:37052262]."},"prefetch_data":{"uniprot":{"accession":"Q8TBK6","full_name":"Zinc finger CCHC domain-containing protein 10","aliases":[],"length_aa":192,"mass_kda":21.0,"function":"","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q8TBK6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZCCHC10","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CPSF6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZCCHC10","total_profiled":1310},"omim":[],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli rim","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZCCHC10"},"hgnc":{"alias_symbol":["FLJ20094"],"prev_symbol":[]},"alphafold":{"accession":"Q8TBK6","domains":[{"cath_id":"-","chopping":"39-95","consensus_level":"medium","plddt":81.9133,"start":39,"end":95}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TBK6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TBK6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TBK6-F1-predicted_aligned_error_v6.png","plddt_mean":62.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZCCHC10","jax_strain_url":"https://www.jax.org/strain/search?query=ZCCHC10"},"sequence":{"accession":"Q8TBK6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TBK6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TBK6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TBK6"}},"corpus_meta":[{"pmid":"24243566","id":"PMC_24243566","title":"Maternal preconception body mass index and offspring cord blood DNA methylation: exploration of early life origins of disease.","date":"2013","source":"Environmental and molecular mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24243566","citation_count":99,"is_preprint":false},{"pmid":"33517196","id":"PMC_33517196","title":"MiR-410-3p activates the NF-κB pathway by targeting ZCCHC10 to promote migration, invasion and EMT of colorectal cancer.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/33517196","citation_count":26,"is_preprint":false},{"pmid":"31138778","id":"PMC_31138778","title":"ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31138778","citation_count":23,"is_preprint":false},{"pmid":"31404068","id":"PMC_31404068","title":"PITX1 protein interacts with ZCCHC10 to regulate hTERT mRNA transcription.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31404068","citation_count":20,"is_preprint":false},{"pmid":"30984102","id":"PMC_30984102","title":"Identification of Shared Genes Between Ischemic Stroke and Parkinson's Disease Using Genome-Wide Association Studies.","date":"2019","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30984102","citation_count":14,"is_preprint":false},{"pmid":"37052262","id":"PMC_37052262","title":"Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia.","date":"2023","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37052262","citation_count":11,"is_preprint":false},{"pmid":"37511041","id":"PMC_37511041","title":"Epigenomics Analysis of the Suppression Role of SIRT1 via H3K9 Deacetylation in Preadipocyte Differentiation.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511041","citation_count":11,"is_preprint":false},{"pmid":"28842203","id":"PMC_28842203","title":"Analysis of the peptides detected in atopic dermatitis and various inflammatory diseases patients-derived sera.","date":"2017","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/28842203","citation_count":7,"is_preprint":false},{"pmid":"41143260","id":"PMC_41143260","title":"Iso-seq and RNA-seq data from ML-2 acute myeloid leukemia cells overexpressing the ZCCHC10 gene.","date":"2025","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/41143260","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6364,"output_tokens":1274,"usd":0.019101},"stage2":{"model":"claude-opus-4-6","input_tokens":4501,"output_tokens":3504,"usd":0.165158},"total_usd":0.184259,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"ZCCHC10 binds p53 directly and stabilizes it by disrupting the interaction between p53 and MDM2, thereby attenuating MDM2-mediated p53 ubiquitination and degradation. This interaction was functionally required for ZCCHC10's tumor-suppressive effects on cell proliferation, migration, invasion, and cisplatin resistance in lung cancer cells harboring wild-type p53, but not in p53-null or p53-mutant cells.\",\n      \"method\": \"Co-immunoprecipitation, overexpression/knockdown with functional rescue using p53 inhibitor pifithrin-α and activator Nutlin3, in vitro and in vivo tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, multiple orthogonal functional assays, genetic epistasis with p53 inhibitor/activator, in vivo validation\",\n      \"pmids\": [\"31138778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZCCHC10 interacts with PITX1 via the PITX1 homeodomain, and the ZCCHC10-PITX1 complex cooperatively suppresses hTERT transcription. Deletion of the PITX1 homeodomain required for ZCCHC10 interaction abolished the transcriptional silencing effect.\",\n      \"method\": \"FLAG pull-down assay, co-expression studies, mutagenesis (homeodomain deletion), luciferase/transcription assays in melanoma cell lines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pulldown plus mutagenesis and functional transcription assay, single lab\",\n      \"pmids\": [\"31404068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-410-3p directly targets the 3'UTR of ZCCHC10 mRNA, reducing ZCCHC10 protein levels. Loss of ZCCHC10 activates the NF-κB signaling pathway, promoting EMT, migration, and invasion in colorectal cancer cells. NF-κB inhibition rescued the pro-invasive phenotype caused by ZCCHC10 knockdown, placing ZCCHC10 upstream of NF-κB as a suppressor.\",\n      \"method\": \"Dual-luciferase reporter assay (miR-410-3p targeting ZCCHC10 3'UTR), siRNA knockdown, NF-κB inhibitor (BAY 11-708) rescue, wound healing and Transwell invasion assays, overexpression rescue\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase validation of direct targeting plus epistasis with NF-κB inhibitor, single lab\",\n      \"pmids\": [\"33517196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The lncRNA SNHG1 epigenetically silences ZCCHC10 by recruiting DNA methyltransferases DNMT1 and DNMT3B to the ZCCHC10 promoter CpG island. SNHG1 contains a binding motif with complementarity to five sites in the ZCCHC10 promoter; deletion of this motif abolished SNHG1-induced ZCCHC10 promoter hypermethylation. Reduced ZCCHC10 expression leads to decreased p53 activation, increased AML cell proliferation, and venetoclax resistance.\",\n      \"method\": \"ChIP assay (SNHG1 binding to ZCCHC10 promoter, DNMT1/DNMT3B recruitment), bisulfite sequencing (promoter methylation), SNHG1 motif-deletion mutagenesis, overexpression/knockdown functional assays, xenograft mouse model\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, methylation assay, mutagenesis, and in vivo xenograft, moderate evidence from single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37052262\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZCCHC10 is a tumor suppressor that stabilizes p53 by competitively disrupting the p53–MDM2 interaction to prevent MDM2-mediated ubiquitination and degradation of p53; it also forms a complex with PITX1 to transcriptionally repress hTERT, and acts upstream of NF-κB to suppress EMT and invasion, while its own expression is silenced by SNHG1-directed recruitment of DNMT1/DNMT3B to its promoter CpG island.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ZCCHC10 functions as a tumor suppressor that stabilizes p53 by directly binding p53 and competitively disrupting the p53–MDM2 interaction, thereby attenuating MDM2-mediated ubiquitination and degradation of p53; this mechanism is required for ZCCHC10's anti-proliferative, anti-invasive, and chemosensitizing activities in wild-type p53-expressing cancer cells [PMID:31138778]. ZCCHC10 also partners with the transcription factor PITX1 via its homeodomain to cooperatively repress hTERT transcription [PMID:31404068], and suppresses NF-κB signaling to inhibit epithelial–mesenchymal transition and invasion [PMID:33517196]. ZCCHC10 expression is epigenetically silenced in cancer through lncRNA SNHG1-directed recruitment of DNMT1 and DNMT3B to its promoter CpG island, leading to promoter hypermethylation and loss of p53 stabilization [PMID:37052262].\",\n  \"teleology\": [\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing ZCCHC10 as a p53 stabilizer resolved how this previously uncharacterized zinc-finger protein suppresses tumor growth: it directly binds p53, disrupts the p53–MDM2 interaction, and blocks MDM2-mediated ubiquitination and degradation of p53, making its tumor-suppressive effects strictly dependent on wild-type p53.\",\n      \"evidence\": \"Reciprocal co-IP, epistasis with p53 inhibitor pifithrin-α and activator Nutlin-3, in vitro and xenograft lung cancer models\",\n      \"pmids\": [\"31138778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for the ZCCHC10–p53 interaction and the precise binding interface on MDM2 are unknown\",\n        \"Whether ZCCHC10 affects MDMX-mediated p53 regulation has not been tested\",\n        \"Endogenous stoichiometry of the ZCCHC10–p53–MDM2 competitive mechanism has not been quantified\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of ZCCHC10 as a PITX1 cofactor that cooperatively represses hTERT transcription revealed a second tumor-suppressive axis independent of p53 stabilization.\",\n      \"evidence\": \"FLAG pull-down, homeodomain-deletion mutagenesis, luciferase reporter assays in melanoma cells\",\n      \"pmids\": [\"31404068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The ZCCHC10–PITX1 interaction has been shown only by pull-down in a single study without reciprocal co-IP\",\n        \"Whether ZCCHC10–PITX1-mediated hTERT repression is functionally relevant in vivo remains untested\",\n        \"The domain in ZCCHC10 required for PITX1 binding is not mapped\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placing ZCCHC10 upstream of NF-κB as a negative regulator explained how its loss promotes EMT, migration, and invasion in colorectal cancer, and revealed miR-410-3p as a post-transcriptional silencer of ZCCHC10.\",\n      \"evidence\": \"Dual-luciferase 3′UTR reporter assay, siRNA knockdown, NF-κB inhibitor (BAY 11-7082) rescue, wound healing and Transwell invasion assays\",\n      \"pmids\": [\"33517196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The molecular mechanism by which ZCCHC10 inhibits NF-κB activation is undefined (direct vs. indirect)\",\n        \"Findings come from a single laboratory without in vivo validation\",\n        \"Relationship between ZCCHC10's NF-κB suppression and its p53 stabilization function is unexplored\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that lncRNA SNHG1 epigenetically silences ZCCHC10 by recruiting DNMT1/DNMT3B to its promoter CpG island explained how ZCCHC10 is downregulated in cancer and linked this silencing to venetoclax resistance in AML via reduced p53 activity.\",\n      \"evidence\": \"ChIP for DNMT1/DNMT3B recruitment, bisulfite sequencing, SNHG1 motif-deletion mutagenesis, xenograft mouse model in AML cells\",\n      \"pmids\": [\"37052262\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SNHG1-mediated silencing of ZCCHC10 operates across cancer types beyond AML is unknown\",\n        \"The extent to which ZCCHC10 promoter methylation accounts for its downregulation relative to miR-410-3p post-transcriptional silencing has not been compared\",\n        \"Whether restoring ZCCHC10 expression alone is sufficient to overcome venetoclax resistance in patient-derived models is untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZCCHC10's zinc-finger CCHC domain contributes to its molecular functions — including p53 binding, PITX1 interaction, and NF-κB suppression — and whether these activities are coordinated or independent in vivo remains an open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural or domain-mapping data exist for ZCCHC10's interactions with p53 or MDM2\",\n        \"No unbiased interactome or proteomics study has been performed for ZCCHC10\",\n        \"The physiological role of ZCCHC10 in normal (non-cancer) tissues is entirely uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005357801\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TP53\", \"MDM2\", \"PITX1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term_ids. Let me correct that.\n\n```json\n{\n  \"mechanistic_narrative\": \"ZCCHC10 functions as a tumor suppressor that stabilizes p53 by directly binding p53 and competitively disrupting the p53–MDM2 interaction, thereby attenuating MDM2-mediated ubiquitination and degradation of p53; this mechanism is required for ZCCHC10's anti-proliferative, anti-invasive, and chemosensitizing activities in wild-type p53-expressing cancer cells [PMID:31138778]. ZCCHC10 also partners with the transcription factor PITX1 via its homeodomain to cooperatively repress hTERT transcription [PMID:31404068], and suppresses NF-κB signaling to inhibit epithelial–mesenchymal transition and invasion [PMID:33517196]. ZCCHC10 expression is epigenetically silenced in cancer through lncRNA SNHG1-directed recruitment of DNMT1 and DNMT3B to its promoter CpG island, leading to promoter hypermethylation and loss of p53 stabilization [PMID:37052262].\",\n  \"teleology\": [\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing ZCCHC10 as a p53 stabilizer resolved how this previously uncharacterized zinc-finger protein suppresses tumor growth: it directly binds p53, disrupts the p53–MDM2 interaction, and blocks MDM2-mediated ubiquitination and degradation of p53, making its tumor-suppressive effects strictly dependent on wild-type p53.\",\n      \"evidence\": \"Reciprocal co-IP, epistasis with p53 inhibitor pifithrin-α and activator Nutlin-3, in vitro and xenograft lung cancer models\",\n      \"pmids\": [\"31138778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for the ZCCHC10–p53 interaction and the precise binding interface on MDM2 are unknown\",\n        \"Whether ZCCHC10 affects MDMX-mediated p53 regulation has not been tested\",\n        \"Endogenous stoichiometry of the ZCCHC10–p53–MDM2 competitive mechanism has not been quantified\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of ZCCHC10 as a PITX1 cofactor that cooperatively represses hTERT transcription revealed a second tumor-suppressive axis independent of p53 stabilization.\",\n      \"evidence\": \"FLAG pull-down, homeodomain-deletion mutagenesis, luciferase reporter assays in melanoma cells\",\n      \"pmids\": [\"31404068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The ZCCHC10–PITX1 interaction has been shown only by pull-down in a single study without reciprocal co-IP\",\n        \"Whether ZCCHC10–PITX1-mediated hTERT repression is functionally relevant in vivo remains untested\",\n        \"The domain in ZCCHC10 required for PITX1 binding is not mapped\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placing ZCCHC10 upstream of NF-κB as a negative regulator explained how its loss promotes EMT, migration, and invasion in colorectal cancer, and revealed miR-410-3p as a post-transcriptional silencer of ZCCHC10.\",\n      \"evidence\": \"Dual-luciferase 3′UTR reporter assay, siRNA knockdown, NF-κB inhibitor (BAY 11-7082) rescue, wound healing and Transwell invasion assays\",\n      \"pmids\": [\"33517196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The molecular mechanism by which ZCCHC10 inhibits NF-κB activation is undefined (direct vs. indirect)\",\n        \"Findings come from a single laboratory without in vivo validation\",\n        \"Relationship between ZCCHC10's NF-κB suppression and its p53 stabilization function is unexplored\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that lncRNA SNHG1 epigenetically silences ZCCHC10 by recruiting DNMT1/DNMT3B to its promoter CpG island explained how ZCCHC10 is downregulated in cancer and linked this silencing to venetoclax resistance in AML via reduced p53 activity.\",\n      \"evidence\": \"ChIP for DNMT1/DNMT3B recruitment, bisulfite sequencing, SNHG1 motif-deletion mutagenesis, xenograft mouse model in AML cells\",\n      \"pmids\": [\"37052262\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SNHG1-mediated silencing of ZCCHC10 operates across cancer types beyond AML is unknown\",\n        \"The extent to which ZCCHC10 promoter methylation accounts for its downregulation relative to miR-410-3p post-transcriptional silencing has not been compared\",\n        \"Whether restoring ZCCHC10 expression alone is sufficient to overcome venetoclax resistance in patient-derived models is untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZCCHC10's zinc-finger CCHC domain contributes to its molecular functions — including p53 binding, PITX1 interaction, and NF-κB suppression — and whether these activities are coordinated or independent in vivo remains an open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural or domain-mapping data exist for ZCCHC10's interactions with p53 or MDM2\",\n        \"No unbiased interactome or proteomics study has been performed for ZCCHC10\",\n        \"The physiological role of ZCCHC10 in normal (non-cancer) tissues is entirely uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TP53\", \"MDM2\", \"PITX1\"],\n    \"other_free_text\": []\n  }\n}\n```"}